RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ono Pharmaceutical Co Stock

Ono Pharmaceutical Co Stocks 2024

Ono Pharmaceutical Co Stocks

480.04 M

Ticker

4528.T

ISIN

JP3197600004

WKN

859650

In 2024, Ono Pharmaceutical Co had 480.04 M outstanding stocks, a -1.7% change from the 488.35 M stocks in the previous year.

The Ono Pharmaceutical Co Stocks history

YEARNUMBER OF STOCKS (undefined JPY)
2027e480.04
2026e480.04
2025e480.04
2024480.04
2023488.35
2022496.53
2021499.2
2020504.04
2019514.17
2018518.43
2017530.05
2016530.04
2015530.05
2014530
2013530
2012530
2011541
2010544
2009550
2008571
2007583
2006587
2005587

Ono Pharmaceutical Co shares outstanding

The number of shares was Ono Pharmaceutical Co in 2023 — This indicates how many shares 488.353 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ono Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ono Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ono Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ono Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ono Pharmaceutical Co Aktienanalyse

What does Ono Pharmaceutical Co do?

Ono Pharmaceutical Co Ltd is a Japanese company specialized in the development and marketing of innovative medications. It has a long history, being founded in 1717. Originally, it was a Chinese medicine business, but since its establishment in 1924, Ono Pharmaceutical has focused on the development of modern medications. The company's business model is based on research and development of medications. Ono Pharmaceutical has several branches in different countries and works closely with research institutions and universities to develop groundbreaking medications. The company is committed to providing innovative therapies to patients worldwide. Ono Pharmaceutical specializes in several areas, including oncology, immunology, neurology, and diabetes. In oncology, the company has launched several medications, including Opdivo and Sprycel, used for the treatment of various forms of cancer. Opdivo is an immunooncological medication that shows great promise and is used worldwide. In immunology, Ono Pharmaceutical has developed a range of medications, including Nivolumab, used for the treatment of various autoimmune diseases such as rheumatoid arthritis. Ono Pharmaceutical has also developed medications for influenza and other types of infections. In the field of neurology, the company has developed medications used for pain treatment, including the compound Fauldopamine. Despite the discovery of Fauldopamine, which is considered suitable for pain treatment, no final decision has been made regarding the application of this medication. In diabetes research, Ono Pharmaceutical has developed various medications used for the treatment of diabetes, including Alogliptin and Canagliflozin. These medications help diabetics better control their blood sugar levels and alleviate the symptoms of this disease. Ono Pharmaceutical has also launched numerous products used in different areas, such as Desitin, a cream for the treatment of skin disorders, or Minon, a skincare line. The company places great importance on collaboration and innovation to provide highly effective medications to patients. Ono Pharmaceutical is committed to expanding its presence in the global market and developing further innovative therapies to improve people's lives. Ono Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Ono Pharmaceutical Co's Shares Outstanding

Ono Pharmaceutical Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Ono Pharmaceutical Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Ono Pharmaceutical Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Ono Pharmaceutical Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Ono Pharmaceutical Co stock

How many stocks are there of Ono Pharmaceutical Co?

The current number of stocks of Ono Pharmaceutical Co is 480.04 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Ono Pharmaceutical Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Ono Pharmaceutical Co evolved in recent years?

The number of shares of Ono Pharmaceutical Co has increased by -1.7% gesunken compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Ono Pharmaceutical Co as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Ono Pharmaceutical Co?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Ono Pharmaceutical Co pay?

Over the past 12 months, Ono Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 4.88 %. For the coming 12 months, Ono Pharmaceutical Co is expected to pay a dividend of 86.14 JPY.

What is the dividend yield of Ono Pharmaceutical Co?

The current dividend yield of Ono Pharmaceutical Co is 4.88 %.

When does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Ono Pharmaceutical Co?

Ono Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Ono Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 86.14 JPY are expected. This corresponds to a dividend yield of 5.26 %.

In which sector is Ono Pharmaceutical Co located?

Ono Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ono Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ono Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Ono Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ono Pharmaceutical Co in the year 2023?

In the year 2023, Ono Pharmaceutical Co distributed 77 JPY as dividends.

In which currency does Ono Pharmaceutical Co pay out the dividend?

The dividends of Ono Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ono Pharmaceutical Co

Our stock analysis for Ono Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.